Back

Prevalence of valvular heart disease in the general population: results from the population based STAAB cohort study

11 May 2024 (08:00 - 20:00)
Organised by: Logo
Congress Presentation Part of: Valvular heart disease 3 Epidemiology, Prognosis, Outcome HFA Premium Access Heart Failure 2024 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Mengmeng Chen

University Hospital Wuerzburg, Wuerzburg (Germany)

7 More presentations in this session

Presentation thumbnail
Exercise-induced tricuspid regurgitation in heart failure, gas exchange profile and outcomes
Doctor G. Mondellini (Rotterdam, NL)
Abstract Slides Video
Presentation thumbnail
Geometry of tricuspid annulus in functional tricuspid regurgitation patients: differences between aetiologies. 3D echocardiography study
Mr D. Verikas (Kaunas, LT)
Abstract Slides Video
Presentation thumbnail
Aortic stenosis and progression of left ventricular dysfunction
Doctor I. Rodrigues (Vila Nova de Gaia, PT)
Abstract Slides Video
Presentation thumbnail
Gender differences in left ventricular systolic function among patients with severe aortic stenosis
Mr A. De Oliveira Carvalho dos Santos (Aveiro, PT)
Abstract Slides Video
Presentation thumbnail
Right ventricular to pulmonary artery uncoupling predicts adverse cardiovascular events in adult patients with right-sided congenital heart diseases.
Doctor G. Iannaccone (Rome, IT)
Abstract Slides Video

Access the full session

Session thumbnail
Valvular heart disease 3

The Event

Event poster

Heart Failure 2024

11 May - 14 May 2024
You may be interested in
thumbnail
Congress Presentation
Frequency, course and prognostic yield of valvular heart disease in the general population- Results from the STAAB cohort study
thumbnail
Congress Presentation
Association between warfarin and direct oral anticoagulants users and risk of mortality: cohort studies in England and Hong Kong
thumbnail
Congress Presentation
Incidence, management and outcomes of patients with incident atrial fibrillation in the contemporary direct oral anti coagulants era. A national study

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources